SHARPIN and neoplasm: Kinetic analysis of the difference in tumor size between the WT and SHARPIN-deficient melanomas in the mice treated with anti-PD1 showed progressive divergence within the same animals (Figure 6F), indicating a local synergy between T cell checkpoint blockade and activation of target cell programmed cell death by T cell–derived TNF.